on the principle that the radioligands will compete with the neurotransmitter for binding to the receptor. High synaptic concentrations of dopamine will result in less radioligand binding whereas lowered synaptic concentration of dopamine will result in more radioligand binding. This phenomenon may prove useful in many studies since by measuring changes in the binding of the radiotracer it may be possible to monitor changes in dopamine levels occurring either as a result of drug treatments or psychiatric diseases. Conversely, in studies where the intention is only to quantify the receptor density, competition of radiotracer binding with the endogenous neurotransmitter can be an additional complication in interpretation of the results from a PET or SPECT study.
The studies performed to date examining competition between endogenous dopamine and D 2 radiotracer binding have involved both rodent studies and primate and human PET studies. For example, in studies in mice, increases in synaptic dopamine produced by amphetamine administration have been found to produce decreases in the in vivo striatal binding of [ 3 H]raclopride, while dopamine depletion with reserpine treatment or gamma-butyrolactone causes significant increases in binding (Ross and Jackson 1989a; Ross 1991; Young et al. 1991) . In PET and SPECT studies in primates and humans increases in the levels of synaptic dopamine produced by administration of either amphetamine or dopamine uptake inhibitors such as cocaine and methylphenidate have similarly been found to produce modest decreases (10-40%) in the binding of (Innis et al. 1992; Volkow et al. 1994; Laruelle et al. 1995; Carson et al. 1997; Laruelle et al. 1997; Volkow et al. 1999) . One frequent observation that has arisen from studies on the effects of changes in dopamine on radiotracer binding in rodent and primate PET studies is that the lower affinity radiotracers, such as raclopride and IBZM (K d of 0.4-1 nM; Kung et al. 1989; Ross and Jackson 1989a) , appear to be more susceptible to competition by synaptic dopamine than other D 2 radiotracers such as epidepride and N-methylspiperone, which have very high receptor affinities (K d Ͻ 0.1 nM). D 1 receptors have been less frequently investigated in imaging studies than D 2 receptors. Most of the available radiotracers have structures based on the D 1 antagonist, SCH 23390, a benzazepine derivative with a K d of 0.1-0.3 nM (Billard et al. 1984; Andersen et al. 1985) . For non-benzazepine compounds the only D 1 radiotracer which has been evaluated so far is [ 11 C]A69024, which was found to be effective at labeling D 1 receptors in vivo despite a relatively low affinity for the receptor (Kassiou et al. 1995) . With regard to the effect of endogenous dopamine on the in vivo binding of D 1 radiotracers, the few studies performed to date have been conducted using benzazepine radiotracers such as SCH 23390 and have indicated that the binding of these radiotracers appears to be relatively resistant to pharmacologically induced changes in dopamine levels (Inoue et al. 1991; Thibaut et al. 1996; Abi-Dargham et al. 1999; Gatley et al. 2000; Gifford et al. 2000) . However, by analogy with the high-affinity D 2 radiotracers, it may be expected that the susceptibility of these high-affinity benzazepine derivatives to competition with dopamine will be limited as a result of their non-reversible and flow-dependent binding kinetics.
Among the 5-HT receptors, only 5-HT 2A and 5-HT 1A receptors have been imaged with PET and SPECT. Although radiotracers against these receptors have been used in a number of studies to measure receptor densities and receptor occupancies achieved by clinical drugs, there is little information currently available on the susceptibility of radiotracers against these receptors to competition with endogenous 5-HT.
Because of the relative paucity of data on the effects of competition with endogenous transmitters on radiotracer binding to D 1 , 5-HT 1A and 5-HT 2A compared with that collected for radiotracer binding to D 2 receptors, the current study was conducted with the objective of determining whether pharmacological altered dopamine and 5-HT levels would affect radiotracer binding to these receptors. The radiotracers we evaluated in the current study were H]Raclopride binding to D 2 receptors was also evaluated for comparative purposes. The radiotracers we examined were selected on the basis of the fact that they have all been previously employed in PET studies and found to be effective in labeling their respective receptors in vivo. Additionally, where possible, the radiotracer we used was one with a relatively moderate receptor affinity and reversible binding kinetics. This was because although these radiotracers give improved receptor quantitation in vivo , they also may be more susceptible to the effects of competition with the endogenous neurotransmitter. Kassiou et al. (1994) , with a specific activity of approximately 85 Ci/mmol. The radiotracers evaluated in the current study and their receptors affinities are summarized in Table 1 .
MATERIALS AND METHODS

Drugs
In vivo Binding
Male Swiss-Webster (25-30g) mice were purchased from Taconic Farms (Germantown, NY) and were injected via the tail vein, with 1 Ci of radiotracer in 0.9% saline. Groups of 5-7 mice were then sacrificed by cervical dislocation at various time points post-injection and the frontal cortex, hippocampus, striatum and cerebellum dissected out. Each tissue sample was weighed and dissolved in tissue solubilizer overnight. UltimaGold XR scintillation fluid was added and tissue radioactivity was determined using a Packard Model 1600 TR liquid scintillation counter.
To determine the effects of pharmacological increases or decreases in dopamine and 5-HT mice were injected intraperitoneally with drugs either prior or following the radiotracer administration. Mice treated with reserpine were warmed on a heating pad prior to the radiotracer administration in order to reduce the effects of the reserpine-induced hypothermia on radiotracer kinetics and binding.
Drugs were administered in 0.9% saline. Exceptions were p-chlorophenylalanine which was dissolved in 40% 2-hydroxypropyl-␤ -cyclodextrin, and reserpine, which was dissolved in a small quantity of lactic acid, diluted with water, and administered immediately.
Measurement of Tissue Levels of 5-HT
The effect of chronic treatment with p-chlorophenylalanine on tissue levels of 5-HT was determined by homogenizing brain tissue in 0.5 M percholoric acid containing 0.1% EDTA. The homogenate was then centrifuged and 5-HT levels in the supernatant measured using high pressure liquid chromatography (HPLC). For HPLC a C18 reverse phase column (Bioanalytical Systems Inc., IN) coupled to an electrochemical detector (Bioanalytical Sytems Inc.) was used. The mobile phase consisted of 8% acetonitrile, 1% tetrahydrofuran,15 mM sodium phosphate, 30 mM sodium citrate, 0.027 mM EDTA, 10 mM diethylamine HCl, 2 mM decanesulphonic acid, pH 4.0.
Data Calculations and Statistics
The percent-injected dose per gram of tissue (% ID/g) was determined by dividing the tissue radioactivity per gram wet weight (DPM/g) by the total radioactivity injected into the animal. The striatum to cerebellum ratio minus one (ST/CE-1) or cortex to cerebellum ratio minus one (CO/CE-1) was calculated by dividing the DPM/g for the striatum or cortex by the DPM/g for the cerebellum. For each radioligand the brain uptake was determined over several time points and this data was then used to determine the optimal sacrifice time for each radiotracer in the in vivo competition studies. Statistical significance was determined using a 1-way analysis of variance (ANOVA), followed by a post-hoc Dunnett's test. H]raclopride uptake indicated that the ST/CE-1 ratios were considerably reduced at the high dose of amphetamine (10 mg/kg, i.p.). However, with the lower dose amphetamine (3 mg/kg, i.p.), or with cocaine, the reduction in ST/CE-1 ratios did not reach significance (Table 2) .
RESULTS
[
To produce dopamine depletion the mice were given either reserpine (5 mg/kg, i.p.) 15 hours prior to the [ 3 H]raclopride administration or 4-hydroxybutyrate H]raclopride accumulation in the striatum should already have peaked and be in the declining (or washout) phase. However, despite the reversal in the order of drug administration, similar effects of amphetamine and 4-hydroxybutyrate on the ST/CE-1 ratios were obtained. The values were as follows: control 4.3 Ϯ 0.4 (7), 10 mg/kg amphetamine 1.9 Ϯ 0.2 (7), 400 mg/kg 4-hydroxybutyrate 7.6 Ϯ 0.4 (6); (values are means Ϯ SEM (n); ANOVA: F(2,17) ϭ 73.7, p Ͻ .01). , in which amphetamine and 4-hydroxybutyrate were given five minutes after radiotracer administration, rather than prior to the radiotracer administration as shown in Table 3 . However, despite the reversal in the order of drug administration, the data obtained was similar. The ST/CE-1 ratios obtained were as follows: control 6.2 Ϯ 0.3 (7), 3 mg/kg amphetamine 6.0 Ϯ 0.4 (6), 10 mg/kg amphetamine 4.2 Ϯ 0.2 (7), 400 mg/kg 4-hydroxybutyrate 6.4 Ϯ 0.5 (7), (data are means Ϯ SEM (n); ANOVA: F(3, 23) ϭ 9.6, p Ͻ .01). Only the high dose of amphetamine produced a change in striatal binding of (Figure 3) . Greatest uptake of this tracer was observed in the striatum, reflecting the high affinity of this tracer for D 2 dopamine receptors. The washout of radiotracer from this region was slow, with only a 5% decline in radiotracer levels from 60 to 240 minutes after radiotracer administration. In contrast to its uptake in the striatum, in the occipital cortex the levels of uptake were smaller and the washout of radiotracer was much faster. Since D 2 receptors are largely absent from the occipital cortex the [ (Table  4 ). In the first series of experiments the effects of fenfluramine on [ 3 H]N-methylspiperone binding was examined. Fenfluramine produced a dose-dependent reduction in cortical NMS binding, with a greater than 50% reduction in the cortical binding at the highest fenfluramine dose. In order to determine if the fenfluramineinduced decreases in 5-HT binding were a consequence of 5-HT release, experiments were conducted in which the fenfluramine was co-administered with the 5-HT uptake blocker, paroxetine. In microdialysis and brain slice experiments, uptake inhibitors such as paroxetine, which by themselves produce only minor effects on extracellular 5-HT, have been consistently found to prevent the much larger levels of 5-HT release produced by releasing agents such as fenfluramine (Raiteri et al. 1995; Gobbi et al. 1998 ). In the [ In a second series of experiments the effect of p-chloroamphetamine on cortical NMS binding was evaluated. However, in contrast to the effects of fenfluramine on [ In a second series of experiments the effects of 5-HT depletion by the 5-HT synthesis inhibitor, p-chlorophenylalanine, was examined. Treatment of the mice with p-chlorophenylalanine (150 mg/kg i.p. twice per day for four days) reduced tissue 5-HT levels in the cortex by 57% (control mice 148 Ϯ 19 ng/g (n ϭ 5); p-chlorophenylalanine mice 63 Ϯ 11 ng/g (n ϭ 5)) and in the hippocampus by 62% (control mice 48 Ϯ 11 ng/g (n ϭ 4); p-chlorophenylalanine mice 18 Ϯ 1 ng/g (n ϭ 4)). However, despite the depletion of tissue 5-HT, there was no indication of an increase in the in vivo cortical or hippocampal [ 3 H]WAY 100635 binding (Table 5) . Rather, the binding appeared to be slightly reduced, although not reaching the level of significance.
DISCUSSION
The degree to which radiotracer binding to a particular G-protein coupled receptor will be sensitive to competition with endogenous transmitters will depend on a number of factors, some of which are related to properties of the receptors and some to the properties of the radioligand (recently reviewed by Laruelle 2000) . For receptor factors, an essential requirement for being able to observe competition is that a significant fraction of the receptor should be (or become) occupied by the transmitter. The greatest sensitivity to increases or decreases in transmitter levels will be obtained if the basal occupancy of the receptor by the transmitter is normally fairly high. Thus if the basal occupancy is normally about 50%, a complete depletion of the endogenous transmitter could potentially produce a 2-fold increase in the amount of specific radiotracer binding, while a doubling of the endogenous transmitter levels would produce a 34% decrease in radiotracer binding. However, if the basal occupancy of the receptor by the endogenous transmitter is only, say, 10%, then a complete depletion of the endogenous transmitter would produce a 11% increase in radiotracer binding to receptors, while a doubling of the endogenous transmitter levels would produce only a 9% fall in radiotracer binding. For a particular receptor a low basal level of occupancy of the receptors by the transmitter will occur if one or more of the following conditions apply: (1) the average synaptic cleft concentration of the transmitter is low; (2) the receptor has a low affinity for the transmitter and/or the receptors are mostly in a low agonist affinity state; (3) the receptors are inaccessible to the transmitter, either as a result of being located at predominantly extrasynaptic rather than synaptic sites or because they are predominantly internalized inside the cell rather than being located on the plasma-membrane.
In addition to receptor factors, the characteristics of the radioligand also can have an effect on susceptibility to competition with endogenous transmitters. Pharmacological interventions which significantly change brain neurotransmitters may in some cases have an effect on cerebral blood flow and/or peripheral radiotracer metabolism and this can in turn alter the brain uptake of the radiotracer and hence obscure the effects of receptorcompetition. In the case of the effects on cerebral blood flow, radiotracers which have very high affinities for their receptor are in general more sensitive to changes in this parameter than lower affinity radiotracers. This is especially the case in situations where the receptor density in the tissue is high, as is the situation for D 1 and D 2 receptors in the striatum for example. In such receptorrich brain regions high affinity radiotracers tend to accumulate in a non-reversible manner and consequently fail to approach a situation, at least within the time course of the experiment, in which equilibrium binding conditions exist (Gifford et al. 1998) . As a result their total accumulation in the target region will depend strongly on their rate of delivery via the blood stream, in addition to the receptor availability in this region.
In the present study competition between endogenous dopamine and radiotracer binding to D 2 dopamine receptors was determined using [ 3 H]raclopride. In the dopamine depletion experiments an approximately 80% increase in [ 3 H]raclopride binding to striatal D 2 receptors was observed after treatment of the mice with reserpine or 4-hydroxybutyrate. This degree of increase in raclopride binding after dopamine depletion was similar to that observed in previous studies and suggests that the basal occupancy of these receptors by dopamine is normally fairly high (Ross and Jackson 1989a; Ross 1991; Young et al. 1991) . If it is assumed that these treatments produce a nearly complete reduction in dopamine levels and that the changes in specific [ 1 Cortex/cerebellum ratio minus one. 2 Hippocampus/cerebellum ratio minus one p-Chloroamphetamine, fenfluramine, MDMA and cocaine were given i.p. 5 min prior to radiotracer (i.v.). For p-chlorophenylalanine the final injection was given 24 h prior to radiotracer. Animals were sacrificed 45 min following radiotracer administration (i.v.) . Data are means (Ϯ S.E.M.) of the number of animals indicated. Experiment #1: Cortex: F(6, 71) ϭ 1.6, not significant, hippocampus: F(6, 71) ϭ 1.5, not significant. Experiment #2: Cortex t (20) ]raclopride binding by the 10 mg/kg dose of amphetamine observed in the present study is similar to or slightly greater that in observed in other studies in rodents using this radiotracer (Ross and Jackson 1989a,b; Ross 1991; Young et al. 1991) .
Whereas 10 mg/kg amphetamine produced a 64% decrease in [ 3 H]raclopride binding, 20 mg/kg cocaine produced only a small decrease in [ 3 H]raclopride binding which did not reach the level of significance. This may reflect that fact that the increase in dopamine levels produced by uptake inhibitors such as cocaine is less than that produced by amphetamine. Thus in microdialysis experiments cocaine at a dose of 20 mg/kg will produce increases in dopamine of about 5-fold (Kuczenski and Segal 1992; Morgan et al. 1997 ) which is about 10 times smaller than that produced by a 10 mg/ kg dose of amphetamine (Kuczenski and Segal 1992) .
The D 1 experiments in the present study were conducted using the non-benzazepine radioligand, [ 3 H]A69024. In contrast to the non-reversible binding kinetics in the striatum observed with D 1 radiotracers such as SCH 23390 and NNC 756 (Halldin et al. 1986; Farde et al. 1987; Halldin et al. 1993 (Inoue et al. 1991; Thibaut et al. 1996; Abi-Dargham et al. 1999; Gifford et al. 2000) . ]A69024 experiments the animals were sacrificed at a 30-min time point after radiotracer administration. This time point was chosen so as to allowing a reasonable length of time for the drug-altered synaptic dopamine levels to affect the striatal radiotracer levels while still obtaining good striatum/cerebellum ratios for the radiotracer binding. This reasoning was based on the assumption that the elevated synaptic dopamine levels may perhaps have a greater effect on the rate of washout of the radiotracer from receptor-rich brain regions than they do on the peak brain uptake in these regions .
Competition between 5-HT and 5-HT 2A receptors in the present study was determined using [ compound releases 5-HT with a potency which is about twice that of fenfluramine (Crespi et al. 1997) 1A receptors in the present study was also found to be insensitive to 5-HT releasing agents. To date, WAY 100635 and its analogues have been the most used radiotracers for in vivo labeling of 5-HT 1A receptors (Pike et al. 1996; Farde et al. 1997; Carson et al. 2000) . [ 3 H]WAY 100635 has a moderate affinity for 5-HT 1A and in the present study showed partial reversibility in its binding kinetics to receptors in the frontal cortex and hippocampus. Competition of WAY 100635 or its analogues with endogenous 5-HT has been briefly examined in two previous studies (Ginovart et al. 2000; Plenevaux et al. 2000) . Both these previous studies used 5-HT uptake inhibitors rather than releasing agents to increase 5-HT levels, despite the fact that microdialysis studies have indicated that the increase in 5-HT levels produced by uptake inhibitors in vivo is much smaller than that produced by releasing agents. In neither of these studies were these compounds found to have a significant effect on radiotracer binding, supporting the data obtained in the present study.
[ 3 H]WAY 100635 binding was not found to be significantly increased by depletion of tissue levels of 5-HT produced by a 4-day treatment with the 5-HT synthesis inhibitor, p-chlorophenylalanine. This data indicates that in addition to being insensitive to increases in 5-HT, [ 3 H]WAY 100635 binding is also insensitive to decreases in the level of this transmitter. It should be noted, however, that although the tissue levels of 5-HT were decreased by more than 50% by the p-chlorophenylalanine treatment it is possible that the extracellular 5-HT levels may have changed by a lesser amount.
In conclusion, the data indicate that of two dopamine radiotracers examined in the present study, [
